Fairvalue-Calculator Fairvalue-Calculator
EN DE

Creative Medical Technology Holdings (CELZ) Fair Value & Analysis

Healthcare · US · Market cap $8.4M

Price$2.00
Fair Value$1.92
Upside-4.0%
Quality95/100
Evidence: Low Range $1.27 – $2.40

Fair value as of: Jun 25, 2026

Analysis

Creative Medical Technology Holdings (CELZ) currently trades at $2.00, while our model-based Fair Value estimate is $1.92 — implying the stock looks roughly 4.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female s…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Creative Medical Technology Holdings (CELZ) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $1.92 versus a price of $2.00 — about −4% (overvalued). Model-based estimate, not financial advice.
What is the fair value of CELZ?
Our 21-model fair value for Creative Medical Technology Holdings is $1.92 (as of Jun 25, 2026), built from audited fundamentals. The current price is $2.00.
What is the quality score of CELZ?
Creative Medical Technology Holdings has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.